focus -WSS

focus

author：explore 2025-10-01 22:16:09 - browse：1

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

WSS

Humana sues Biden admin over Medicare Advantage audit rule

'Make People Better': The CRISPR babies story you probably don't know

SCOTUS questions limit to govt efforts to fight misinformation

Gene editing the human germline: What are the risks?

Advances in CAR

Creating egg and sperm cells from stem cells raises ethical issues

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

House transparency, PBM reform bill gains bipartisan support

Hollywood unions extend contract negotiations for actors

Snackable artificial intelligence, expert AI, and the pharma industry

Apple is now the first public company to be valued at $3 trillion

Stem cell treatment guidelines are released by FDA

Cancer drug shortages should be causing more outrage

Ethical issues complicate the benefits of medical crowdfunding

Anesthesiologist group: stop taking Ozempic before surgery

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

focus

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Nurses recount patients attacks

The (many) problems with a new study criticizing cancer screening

Orchard's therapy for neuron disease in children wins FDA approval

ALS advocates say criticism of new drugs misses bigger picture

Creating egg and sperm cells from stem cells raises ethical issues

knowledge

explore

explore

knowledge